Willa L. Thorson

Willa L. Thorson

Auto-generated profile, based on publicly available information

Willa L. Thorson

Jackson Memorial Health System, University of Miami Miller School of Medicine 2 Department of Pediatrics, Division of Genetics Miami, FL

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
AHAnthony R. Hogan
Anthony R. Hogan
KRKrishnamurti Amrit Rao
Krishnamurti Amrit Rao
WTWilla L. Thorson
Willa L. Thorson
HNHolly L. Neville
Holly L. Neville
JSJuan E. Sola
Juan E. Sola
EPEduardo Alfonso Perez
Eduardo Alfonso Perez
Waardenburg syndrome (WS) type IV is characterized by pigmentary abnormalities, deafness and Hirschsprung's disease. This syndrome can be triggered by dysregulation of the SOX10 gene, which belongs to the SOX (SRY-related high-mobility group-box) family of genes. We discuss the first known case of a SOX10 frameshift mutation variant defined as c.895delC causing WS type IV without Hirschsprung's disease. This female patient of unrelated Kuwaiti parents, who tested negative for cystic fibrosis and Hirschsprung's disease, was born with meconium ileus and malrotation and had multiple surgical complications likely due to chronic intestinal pseudo-obstruction. These complications included small intestinal necrosis requiring resection, development of a spontaneous fistula between the duodenum and jejunum after being left in discontinuity, and short gut syndrome. This case and previously reported cases demonstrate that SOX10 gene sequencing is a consideration in WS patients without aganglionosis but with intestinal dysfunction.

4 May 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
MGMelissa Gans
Melissa Gans
MWMatthew Wyke
Matthew Wyke
KSKayra Somay
Kayra Somay
WTWilla Thorson
Willa Thorson
DBDusan Bogunovic
Dusan Bogunovic
Immune dysregulation in Down syndrome (DS) is a highly clinically relevant yet underrecognized feature of this common genetic syndrome. Infection is the leading cause of mortality in DS. This infectious risk likely stems from underlying immunodeficiency compounded by their unique intrinsic anatomy. Furthermore, individuals with DS display a broad range of autoinflammatory and autoimmune diseases, spanning dermatologic, neurologic, and metabolic features, which are often difficult to treat with immunomodulators. Through real clinical vignettes of our patients, we will describe how we treat immune dysregulation in DS.